Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematologic Neoplasms | 31 | 2024 | 1890 | 6.260 |
Why?
|
Myelodysplastic Syndromes | 23 | 2023 | 1392 | 5.060 |
Why?
|
Terminal Care | 12 | 2023 | 1750 | 2.110 |
Why?
|
Neoplasms | 30 | 2024 | 22030 | 1.970 |
Why?
|
Geriatric Assessment | 12 | 2024 | 1404 | 1.860 |
Why?
|
Cancer Care Facilities | 6 | 2024 | 424 | 1.640 |
Why?
|
Hospice Care | 10 | 2023 | 677 | 1.630 |
Why?
|
Anemia | 5 | 2023 | 1504 | 1.420 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 11 | 2023 | 1402 | 1.390 |
Why?
|
Leukemia, Myeloid, Acute | 13 | 2024 | 3599 | 1.370 |
Why?
|
Hematopoietic Stem Cell Transplantation | 13 | 2024 | 5649 | 1.320 |
Why?
|
Health Care Rationing | 3 | 2021 | 434 | 1.290 |
Why?
|
Ethics Consultation | 3 | 2024 | 59 | 1.260 |
Why?
|
Leukemia | 3 | 2024 | 1519 | 1.100 |
Why?
|
Antineoplastic Agents | 18 | 2024 | 13591 | 1.080 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2024 | 296 | 1.070 |
Why?
|
Quality of Life | 22 | 2024 | 13286 | 1.010 |
Why?
|
Bone Marrow Examination | 3 | 2016 | 154 | 1.010 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 1 | 2023 | 15 | 0.890 |
Why?
|
Medical Oncology | 10 | 2023 | 2312 | 0.880 |
Why?
|
Bone Marrow Cells | 3 | 2016 | 2414 | 0.830 |
Why?
|
Marketing of Health Services | 2 | 2014 | 150 | 0.740 |
Why?
|
Aged | 73 | 2024 | 168217 | 0.720 |
Why?
|
Artificial Intelligence | 3 | 2024 | 2551 | 0.700 |
Why?
|
Multiple Myeloma | 8 | 2023 | 5129 | 0.700 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 851 | 0.700 |
Why?
|
Humans | 145 | 2024 | 758381 | 0.680 |
Why?
|
Empathy | 1 | 2024 | 473 | 0.670 |
Why?
|
Quality of Health Care | 5 | 2018 | 4317 | 0.650 |
Why?
|
Specimen Handling | 2 | 2014 | 707 | 0.640 |
Why?
|
Blood Transfusion | 3 | 2020 | 1321 | 0.630 |
Why?
|
Resource Allocation | 1 | 2021 | 349 | 0.630 |
Why?
|
Hepatitis B | 1 | 2024 | 701 | 0.620 |
Why?
|
Awareness | 2 | 2015 | 644 | 0.620 |
Why?
|
Internet | 2 | 2024 | 3082 | 0.620 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 5 | 2014 | 693 | 0.600 |
Why?
|
State Government | 1 | 2021 | 381 | 0.590 |
Why?
|
Aged, 80 and over | 37 | 2024 | 58681 | 0.580 |
Why?
|
Hematology | 5 | 2020 | 241 | 0.580 |
Why?
|
Standard of Care | 1 | 2021 | 550 | 0.560 |
Why?
|
Hematinics | 3 | 2016 | 280 | 0.550 |
Why?
|
Salaries and Fringe Benefits | 1 | 2019 | 257 | 0.550 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 563 | 0.540 |
Why?
|
Hemoglobins | 2 | 2020 | 1519 | 0.530 |
Why?
|
Radiation Oncology | 1 | 2022 | 563 | 0.530 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2015 | 237 | 0.520 |
Why?
|
Disease Management | 4 | 2020 | 2500 | 0.520 |
Why?
|
Cause of Death | 2 | 2017 | 3674 | 0.520 |
Why?
|
Patient Selection | 4 | 2020 | 4244 | 0.520 |
Why?
|
Drug Industry | 3 | 2016 | 787 | 0.510 |
Why?
|
Clinical Trials as Topic | 4 | 2024 | 7985 | 0.510 |
Why?
|
SEER Program | 7 | 2018 | 1530 | 0.500 |
Why?
|
Drug Substitution | 1 | 2018 | 288 | 0.500 |
Why?
|
Male | 75 | 2024 | 358742 | 0.490 |
Why?
|
Health Services Accessibility | 3 | 2024 | 5403 | 0.480 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7377 | 0.460 |
Why?
|
Female | 79 | 2024 | 390316 | 0.460 |
Why?
|
United States | 34 | 2024 | 72140 | 0.460 |
Why?
|
Search Engine | 1 | 2015 | 140 | 0.460 |
Why?
|
Vincristine | 5 | 2022 | 1038 | 0.460 |
Why?
|
Frail Elderly | 6 | 2023 | 752 | 0.460 |
Why?
|
Hospices | 3 | 2023 | 245 | 0.450 |
Why?
|
Climate Change | 1 | 2020 | 487 | 0.450 |
Why?
|
Referral and Consultation | 5 | 2022 | 3586 | 0.440 |
Why?
|
Environmental Monitoring | 1 | 2020 | 1445 | 0.440 |
Why?
|
Perception | 4 | 2018 | 1196 | 0.430 |
Why?
|
Glucaric Acid | 1 | 2012 | 9 | 0.430 |
Why?
|
Comorbidity | 8 | 2021 | 10495 | 0.430 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2018 | 3990 | 0.430 |
Why?
|
Iron-Dextran Complex | 1 | 2012 | 13 | 0.420 |
Why?
|
Consumer Health Information | 1 | 2015 | 210 | 0.420 |
Why?
|
Drugs, Generic | 1 | 2018 | 444 | 0.420 |
Why?
|
Middle Aged | 55 | 2024 | 219560 | 0.410 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15785 | 0.410 |
Why?
|
Economics, Pharmaceutical | 1 | 2012 | 87 | 0.400 |
Why?
|
Medicare | 9 | 2023 | 6741 | 0.400 |
Why?
|
Lymphoma | 1 | 2021 | 1896 | 0.390 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10146 | 0.380 |
Why?
|
Bone Marrow Transplantation | 1 | 2019 | 2693 | 0.370 |
Why?
|
Ferric Compounds | 1 | 2012 | 377 | 0.360 |
Why?
|
Physician-Patient Relations | 7 | 2024 | 3242 | 0.340 |
Why?
|
Palliative Care | 5 | 2021 | 3570 | 0.340 |
Why?
|
Databases, Factual | 3 | 2016 | 7980 | 0.340 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 11709 | 0.330 |
Why?
|
Quality Indicators, Health Care | 2 | 2016 | 1797 | 0.330 |
Why?
|
Patient Preference | 4 | 2019 | 921 | 0.320 |
Why?
|
Socioeconomic Factors | 5 | 2019 | 7817 | 0.320 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 935 | 0.320 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 511 | 0.310 |
Why?
|
Population Surveillance | 3 | 2017 | 2606 | 0.310 |
Why?
|
Radiotherapy | 2 | 2017 | 1504 | 0.310 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 25953 | 0.310 |
Why?
|
Symbolism | 1 | 2008 | 34 | 0.310 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2012 | 368 | 0.300 |
Why?
|
Prognosis | 17 | 2023 | 29558 | 0.300 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3175 | 0.290 |
Why?
|
Adult | 39 | 2024 | 219916 | 0.290 |
Why?
|
Survival Analysis | 8 | 2018 | 10112 | 0.290 |
Why?
|
Telemedicine | 1 | 2024 | 3018 | 0.280 |
Why?
|
Lymphoproliferative Disorders | 1 | 2010 | 533 | 0.270 |
Why?
|
Delayed Diagnosis | 1 | 2010 | 463 | 0.270 |
Why?
|
Drug Utilization | 1 | 2012 | 1187 | 0.270 |
Why?
|
Transplantation Conditioning | 1 | 2013 | 1588 | 0.260 |
Why?
|
Health Expenditures | 2 | 2018 | 2348 | 0.260 |
Why?
|
Multivariate Analysis | 6 | 2019 | 12096 | 0.250 |
Why?
|
Physicians, Primary Care | 1 | 2012 | 624 | 0.250 |
Why?
|
Biological Specimen Banks | 2 | 2022 | 782 | 0.250 |
Why?
|
Janus Kinase 2 | 1 | 2008 | 537 | 0.240 |
Why?
|
Blood Coagulation Disorders | 1 | 2008 | 349 | 0.240 |
Why?
|
Risk Assessment | 5 | 2019 | 23883 | 0.240 |
Why?
|
Survival Rate | 9 | 2022 | 12721 | 0.240 |
Why?
|
Greenhouse Effect | 1 | 2024 | 31 | 0.240 |
Why?
|
Information Dissemination | 4 | 2016 | 1128 | 0.240 |
Why?
|
Cognition Disorders | 1 | 2018 | 3975 | 0.240 |
Why?
|
Age Factors | 7 | 2024 | 18357 | 0.230 |
Why?
|
Mastectomy | 2 | 2024 | 1832 | 0.220 |
Why?
|
Positron-Emission Tomography | 3 | 2015 | 6457 | 0.220 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2013 | 1373 | 0.220 |
Why?
|
Doxorubicin | 4 | 2014 | 2209 | 0.220 |
Why?
|
Bupropion | 1 | 2005 | 304 | 0.220 |
Why?
|
Central Nervous System Neoplasms | 1 | 2011 | 916 | 0.210 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1668 | 0.210 |
Why?
|
Massachusetts | 4 | 2024 | 8823 | 0.210 |
Why?
|
Retrospective Studies | 18 | 2024 | 80170 | 0.210 |
Why?
|
Self Report | 4 | 2018 | 3712 | 0.210 |
Why?
|
Disease Progression | 3 | 2024 | 13468 | 0.210 |
Why?
|
Molecular Targeted Therapy | 2 | 2016 | 2796 | 0.210 |
Why?
|
Ethics, Clinical | 1 | 2023 | 101 | 0.210 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2010 | 1627 | 0.200 |
Why?
|
Logistic Models | 7 | 2019 | 13276 | 0.200 |
Why?
|
Employment | 2 | 2019 | 1112 | 0.200 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2005 | 489 | 0.200 |
Why?
|
Bilirubin | 1 | 2024 | 437 | 0.200 |
Why?
|
Prospective Studies | 13 | 2023 | 54136 | 0.200 |
Why?
|
Cohort Studies | 15 | 2016 | 41252 | 0.200 |
Why?
|
Dioxygenases | 1 | 2024 | 332 | 0.190 |
Why?
|
Marital Status | 1 | 2023 | 432 | 0.190 |
Why?
|
Patients | 3 | 2018 | 904 | 0.190 |
Why?
|
Health Care Costs | 1 | 2015 | 3245 | 0.190 |
Why?
|
Insurance, Health | 2 | 2013 | 2495 | 0.190 |
Why?
|
Electronic Health Records | 1 | 2018 | 4761 | 0.190 |
Why?
|
Treatment Outcome | 16 | 2024 | 64379 | 0.190 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 92 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 5 | 2019 | 6493 | 0.180 |
Why?
|
Intensive Care Units | 3 | 2019 | 3732 | 0.180 |
Why?
|
Psychometrics | 3 | 2016 | 3050 | 0.180 |
Why?
|
Consensus | 2 | 2020 | 3099 | 0.180 |
Why?
|
Patient Rights | 1 | 2021 | 125 | 0.170 |
Why?
|
Prednisone | 3 | 2014 | 1565 | 0.170 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 2 | 2016 | 16 | 0.170 |
Why?
|
Mutation | 5 | 2024 | 29915 | 0.170 |
Why?
|
Risk Factors | 11 | 2023 | 73806 | 0.170 |
Why?
|
Hospital Bed Capacity | 1 | 2021 | 207 | 0.170 |
Why?
|
Polypharmacy | 1 | 2022 | 305 | 0.170 |
Why?
|
Thrombosis | 2 | 2016 | 2929 | 0.170 |
Why?
|
Social Class | 3 | 2018 | 1999 | 0.170 |
Why?
|
Hospitalization | 4 | 2022 | 10653 | 0.170 |
Why?
|
Activities of Daily Living | 2 | 2019 | 2414 | 0.170 |
Why?
|
Patient Education as Topic | 1 | 2009 | 2307 | 0.160 |
Why?
|
Pharmacies | 1 | 2021 | 163 | 0.160 |
Why?
|
Social Justice | 1 | 2024 | 479 | 0.160 |
Why?
|
Cyclophosphamide | 3 | 2014 | 2218 | 0.160 |
Why?
|
Lymphoma, Follicular | 2 | 2013 | 453 | 0.160 |
Why?
|
Decision Making, Organizational | 1 | 2019 | 136 | 0.160 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2013 | 685 | 0.160 |
Why?
|
Cytogenetic Analysis | 1 | 2019 | 270 | 0.160 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2024 | 1791 | 0.160 |
Why?
|
United States Food and Drug Administration | 3 | 2016 | 1660 | 0.150 |
Why?
|
Diterpenes | 1 | 2019 | 169 | 0.150 |
Why?
|
Blood Donors | 1 | 2020 | 343 | 0.150 |
Why?
|
Humanities | 1 | 2018 | 55 | 0.150 |
Why?
|
Models, Biological | 1 | 2014 | 9461 | 0.150 |
Why?
|
Prevalence | 3 | 2021 | 15646 | 0.150 |
Why?
|
Proportional Hazards Models | 7 | 2023 | 12440 | 0.150 |
Why?
|
Health Priorities | 1 | 2021 | 375 | 0.150 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 927 | 0.150 |
Why?
|
Politics | 1 | 2024 | 815 | 0.150 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3526 | 0.150 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 3867 | 0.150 |
Why?
|
Health Care Surveys | 2 | 2017 | 2432 | 0.140 |
Why?
|
HIV Infections | 1 | 2024 | 17275 | 0.140 |
Why?
|
Myeloproliferative Disorders | 1 | 2023 | 606 | 0.140 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 373 | 0.140 |
Why?
|
Odds Ratio | 4 | 2019 | 9650 | 0.140 |
Why?
|
Delphi Technique | 1 | 2020 | 829 | 0.140 |
Why?
|
Patient Participation | 1 | 2006 | 1436 | 0.140 |
Why?
|
Documentation | 1 | 2023 | 892 | 0.140 |
Why?
|
Off-Label Use | 1 | 2018 | 185 | 0.140 |
Why?
|
Neoplasm Staging | 5 | 2020 | 11152 | 0.140 |
Why?
|
Communication | 3 | 2019 | 3846 | 0.130 |
Why?
|
Transplantation, Autologous | 3 | 2023 | 2114 | 0.130 |
Why?
|
Hand Strength | 1 | 2019 | 452 | 0.130 |
Why?
|
Leukemia, Myeloid | 1 | 2019 | 695 | 0.130 |
Why?
|
Time Factors | 7 | 2016 | 39873 | 0.130 |
Why?
|
Uncertainty | 1 | 2021 | 751 | 0.130 |
Why?
|
Breast Neoplasms | 4 | 2024 | 21017 | 0.130 |
Why?
|
Transplantation, Homologous | 3 | 2020 | 4809 | 0.130 |
Why?
|
Periodicals as Topic | 1 | 2007 | 1462 | 0.130 |
Why?
|
Acute Disease | 2 | 2024 | 7225 | 0.130 |
Why?
|
Cytogenetics | 1 | 2016 | 198 | 0.130 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2016 | 92 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1172 | 0.130 |
Why?
|
Neutrophils | 2 | 2024 | 3765 | 0.120 |
Why?
|
Stem Cell Transplantation | 2 | 2013 | 1599 | 0.120 |
Why?
|
Azacitidine | 1 | 2016 | 334 | 0.120 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2016 | 342 | 0.120 |
Why?
|
Diagnostic Self Evaluation | 1 | 2016 | 225 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1788 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20500 | 0.120 |
Why?
|
Minority Groups | 1 | 2021 | 1206 | 0.120 |
Why?
|
Vitamin K | 1 | 2016 | 318 | 0.120 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2014 | 95 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2019 | 907 | 0.110 |
Why?
|
Graft vs Host Disease | 2 | 2018 | 3024 | 0.110 |
Why?
|
Public Opinion | 1 | 2018 | 482 | 0.110 |
Why?
|
Sulfonamides | 1 | 2023 | 1973 | 0.110 |
Why?
|
Gait | 1 | 2019 | 812 | 0.110 |
Why?
|
Communicable Disease Control | 1 | 2020 | 842 | 0.110 |
Why?
|
Critical Illness | 2 | 2017 | 2703 | 0.110 |
Why?
|
Economics | 1 | 2014 | 141 | 0.110 |
Why?
|
Morbidity | 1 | 2019 | 1754 | 0.110 |
Why?
|
Smoking Cessation | 1 | 2005 | 2049 | 0.110 |
Why?
|
Focus Groups | 2 | 2020 | 1382 | 0.110 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3362 | 0.110 |
Why?
|
Patient Care | 1 | 2018 | 622 | 0.110 |
Why?
|
Reference Values | 1 | 2020 | 4919 | 0.110 |
Why?
|
Hodgkin Disease | 2 | 2011 | 1377 | 0.110 |
Why?
|
Data Collection | 3 | 2023 | 3322 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2016 | 638 | 0.100 |
Why?
|
Follow-Up Studies | 8 | 2019 | 39060 | 0.100 |
Why?
|
Sex Factors | 2 | 2016 | 10505 | 0.100 |
Why?
|
Primary Health Care | 1 | 2008 | 4653 | 0.100 |
Why?
|
Lymphoma, T-Cell | 1 | 2014 | 304 | 0.100 |
Why?
|
Memory, Short-Term | 1 | 2018 | 979 | 0.100 |
Why?
|
Pilot Projects | 2 | 2023 | 8554 | 0.100 |
Why?
|
Melphalan | 1 | 2013 | 420 | 0.100 |
Why?
|
Affect | 1 | 2019 | 1480 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2019 | 932 | 0.090 |
Why?
|
Sweating | 1 | 2012 | 154 | 0.090 |
Why?
|
Benzamides | 2 | 2013 | 1368 | 0.090 |
Why?
|
Blood Cell Count | 1 | 2012 | 395 | 0.090 |
Why?
|
Leukocyte Count | 2 | 2024 | 1593 | 0.090 |
Why?
|
Caregivers | 3 | 2023 | 2224 | 0.090 |
Why?
|
Sampling Studies | 1 | 2012 | 614 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2016 | 1673 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 319 | 0.090 |
Why?
|
Income | 2 | 2016 | 1872 | 0.090 |
Why?
|
Drug Evaluation | 1 | 2011 | 638 | 0.090 |
Why?
|
Injections, Intravenous | 1 | 2012 | 1378 | 0.090 |
Why?
|
Cost Sharing | 1 | 2013 | 410 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1141 | 0.090 |
Why?
|
Inappropriate Prescribing | 1 | 2012 | 209 | 0.090 |
Why?
|
Professional Practice | 1 | 2012 | 313 | 0.090 |
Why?
|
Sunlight | 1 | 2011 | 337 | 0.080 |
Why?
|
Fatigue | 1 | 2017 | 1542 | 0.080 |
Why?
|
Classification | 1 | 2010 | 127 | 0.080 |
Why?
|
Drug Information Services | 1 | 2009 | 51 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1056 | 0.080 |
Why?
|
Insurance Coverage | 2 | 2018 | 1933 | 0.080 |
Why?
|
Regression Analysis | 1 | 2019 | 6353 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 1 | 2022 | 3384 | 0.080 |
Why?
|
Health Personnel | 1 | 2023 | 3311 | 0.080 |
Why?
|
Recurrence | 2 | 2012 | 8426 | 0.080 |
Why?
|
Databases as Topic | 1 | 2010 | 472 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1372 | 0.080 |
Why?
|
Renal Dialysis | 1 | 2018 | 1786 | 0.080 |
Why?
|
Analysis of Variance | 1 | 2017 | 6233 | 0.080 |
Why?
|
Medicaid | 2 | 2013 | 2807 | 0.080 |
Why?
|
Developing Countries | 1 | 2021 | 2866 | 0.080 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2016 | 985 | 0.080 |
Why?
|
Intubation, Intratracheal | 1 | 2016 | 1327 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4839 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1110 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2013 | 970 | 0.080 |
Why?
|
Cytarabine | 2 | 2021 | 696 | 0.080 |
Why?
|
Motivation | 1 | 2018 | 1996 | 0.070 |
Why?
|
Psycholinguistics | 1 | 2008 | 79 | 0.070 |
Why?
|
Depression | 3 | 2023 | 8057 | 0.070 |
Why?
|
Patient Transfer | 1 | 2014 | 777 | 0.070 |
Why?
|
Watchful Waiting | 1 | 2012 | 509 | 0.070 |
Why?
|
Anticoagulants | 2 | 2016 | 4778 | 0.070 |
Why?
|
Iron | 1 | 2016 | 1786 | 0.070 |
Why?
|
Veterans | 1 | 2021 | 2631 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1067 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1855 | 0.070 |
Why?
|
International Cooperation | 1 | 2013 | 1430 | 0.070 |
Why?
|
Education, Medical | 1 | 2018 | 1725 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2013 | 1268 | 0.070 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9575 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1613 | 0.070 |
Why?
|
Mass Media | 1 | 2009 | 301 | 0.070 |
Why?
|
Ultraviolet Rays | 1 | 2011 | 1076 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1415 | 0.070 |
Why?
|
Piperazines | 2 | 2013 | 2511 | 0.070 |
Why?
|
Pathology, Clinical | 1 | 2010 | 375 | 0.070 |
Why?
|
Young Adult | 6 | 2019 | 58808 | 0.060 |
Why?
|
Drug Costs | 1 | 2013 | 1179 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5273 | 0.060 |
Why?
|
Poverty | 2 | 2014 | 2692 | 0.060 |
Why?
|
International Agencies | 2 | 2017 | 243 | 0.060 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2012 | 1110 | 0.060 |
Why?
|
Pyrimidines | 2 | 2013 | 3006 | 0.060 |
Why?
|
Patient Care Team | 1 | 2016 | 2504 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 2416 | 0.060 |
Why?
|
Duffy Blood-Group System | 1 | 2024 | 60 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2004 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2014 | 5864 | 0.060 |
Why?
|
Hospitals, General | 1 | 2008 | 795 | 0.060 |
Why?
|
World Health Organization | 1 | 2010 | 1312 | 0.060 |
Why?
|
Mental Disorders | 1 | 2023 | 6803 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3417 | 0.060 |
Why?
|
Cognition | 1 | 2021 | 6955 | 0.050 |
Why?
|
Vitamins | 1 | 2011 | 1632 | 0.050 |
Why?
|
Health Status | 1 | 2016 | 4069 | 0.050 |
Why?
|
Aging | 2 | 2022 | 8651 | 0.050 |
Why?
|
Patient Satisfaction | 2 | 2019 | 3446 | 0.050 |
Why?
|
Ontario | 1 | 2023 | 397 | 0.050 |
Why?
|
Anxiety | 3 | 2023 | 4538 | 0.050 |
Why?
|
Registries | 4 | 2013 | 8176 | 0.050 |
Why?
|
DNA Methylation | 1 | 2016 | 4373 | 0.050 |
Why?
|
Mammaplasty | 2 | 2024 | 1239 | 0.050 |
Why?
|
Medication Adherence | 1 | 2013 | 2155 | 0.050 |
Why?
|
Endoscopy | 1 | 2012 | 1834 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5331 | 0.050 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 350 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2019 | 14481 | 0.050 |
Why?
|
Critical Care | 1 | 2014 | 2692 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2024 | 419 | 0.050 |
Why?
|
Breast Implants | 1 | 2024 | 409 | 0.050 |
Why?
|
Technology | 1 | 2023 | 292 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2008 | 1533 | 0.040 |
Why?
|
Weight Loss | 1 | 2012 | 2671 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 2 | 2013 | 5629 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 12951 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8611 | 0.040 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2022 | 220 | 0.040 |
Why?
|
Boston | 2 | 2019 | 9304 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2016 | 20052 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 4106 | 0.040 |
Why?
|
Secondary Prevention | 1 | 2005 | 1475 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5248 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4581 | 0.040 |
Why?
|
Vitamin D | 1 | 2011 | 3283 | 0.040 |
Why?
|
Adolescent | 5 | 2023 | 87888 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2019 | 321 | 0.040 |
Why?
|
Anthracyclines | 1 | 2019 | 282 | 0.030 |
Why?
|
Breast Implantation | 1 | 2019 | 222 | 0.030 |
Why?
|
Dexamethasone | 1 | 2023 | 1927 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2006 | 2751 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 9273 | 0.030 |
Why?
|
North America | 1 | 2018 | 1276 | 0.030 |
Why?
|
Enteropathy-Associated T-Cell Lymphoma | 1 | 2014 | 13 | 0.030 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2014 | 40 | 0.030 |
Why?
|
Body Mass Index | 2 | 2016 | 12876 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 165 | 0.030 |
Why?
|
Markov Chains | 1 | 2016 | 965 | 0.030 |
Why?
|
Algorithms | 1 | 2014 | 13959 | 0.030 |
Why?
|
Bone Marrow | 1 | 2023 | 2909 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2024 | 2980 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2002 | 2690 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 2014 | 232 | 0.030 |
Why?
|
Anemia, Aplastic | 1 | 2014 | 228 | 0.030 |
Why?
|
Quality Improvement | 2 | 2019 | 3806 | 0.030 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 167 | 0.030 |
Why?
|
Educational Status | 1 | 2019 | 2513 | 0.020 |
Why?
|
Health Services Research | 1 | 2019 | 1812 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4485 | 0.020 |
Why?
|
New England | 1 | 2014 | 1053 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2005 | 12262 | 0.020 |
Why?
|
Teaching | 1 | 2018 | 1168 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2022 | 2714 | 0.020 |
Why?
|
Faculty, Medical | 1 | 2018 | 1192 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1722 | 0.020 |
Why?
|
Social Support | 1 | 2019 | 2153 | 0.020 |
Why?
|
Life Expectancy | 1 | 2016 | 1244 | 0.020 |
Why?
|
Gene Expression | 1 | 2022 | 7583 | 0.020 |
Why?
|
Insurance | 1 | 2011 | 113 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1871 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 2629 | 0.020 |
Why?
|
New York | 1 | 2011 | 874 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3671 | 0.020 |
Why?
|
Program Development | 1 | 2013 | 1297 | 0.020 |
Why?
|
California | 1 | 2011 | 1419 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2013 | 2675 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8530 | 0.020 |
Why?
|
Students, Medical | 1 | 2018 | 1927 | 0.020 |
Why?
|
Bone Diseases | 1 | 2009 | 419 | 0.020 |
Why?
|
Back Pain | 1 | 2009 | 543 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2022 | 10171 | 0.010 |
Why?
|
Decision Making | 1 | 2018 | 3915 | 0.010 |
Why?
|
Cost of Illness | 1 | 2014 | 1936 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5484 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2825 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2013 | 2058 | 0.010 |
Why?
|
Chronic Disease | 1 | 2018 | 9266 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6154 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6821 | 0.010 |
Why?
|
Observer Variation | 1 | 2008 | 2600 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10719 | 0.010 |
Why?
|
Nurses | 1 | 2011 | 2467 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11070 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21273 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2011 | 1832 | 0.010 |
Why?
|
Dietary Supplements | 1 | 2011 | 3388 | 0.010 |
Why?
|
Kidney Diseases | 1 | 2009 | 2083 | 0.010 |
Why?
|
Diet | 1 | 2011 | 8003 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15225 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 42058 | 0.010 |
Why?
|
Child | 1 | 2014 | 79813 | 0.000 |
Why?
|